News Articles Tagged: Preclinical Oncology

Veliparib in Preclinical Cancer Models: Supplier Insights for Researchers

Insights into Veliparib's use in preclinical cancer models and how to source this PARP inhibitor from a reliable China supplier.

Understanding the Preclinical Profile of Y15 (1,2,4,5-Benzenetetramine Tetrahydrochloride) as a FAK Inhibitor

Explore the preclinical data on Y15 (CAS 4506-66-5) as a FAK inhibitor. Learn about its pharmacokinetics and toxicity from a reliable supplier of research chemicals.

SBE 13 Hydrochloride: A Leading PLK1 Inhibitor for Preclinical Oncology Studies

Explore SBE 13 Hydrochloride's role in preclinical oncology studies as a leading PLK1 inhibitor. Learn how it aids in understanding cancer cell proliferation reduction and apoptosis induction, and its importance for suppliers.

IPI-549: A Deep Dive into a Selective PI3Kγ Inhibitor for Preclinical Research

A detailed examination of IPI-549 (Eganelisib), its properties as a selective PI3Kγ inhibitor, and its applications in preclinical research for oncology and inflammatory diseases.

CB-839: A Versatile GLS1 Inhibitor for Preclinical Oncology Studies

Discover the preclinical applications of CB-839, a potent glutaminase GLS1 inhibitor, in various cancer models and combination therapies.

Preclinical Safety Profile of Novel Gefitinib-Triazole Derivatives for Lung Cancer

NINGBO INNO PHARMCHEM CO.,LTD. presents findings on the preclinical safety of new gefitinib-1,2,3-triazole derivatives, highlighting their low toxicity and potential for clinical use.